jeudi 26 octobre 2017

technical approach of Barclays @ Aiken Advocate

Above the Rising Trendline Are Shares of Barclays Plc (BARC.L)

October 26, 2017
In the latest session, Barclays Plc (BARC.L) moved -1.00%, touching a recent bid of 197.00.  Current price levels place the shares above the rising trendline.  
A principle of technical analysis is that once a trend has been formed (two or more peaks/troughs have touched the trendline and reversed direction) it will remain intact until broken. That sounds much more simplistic than it is! The goal is to analyze the current trend using trendlines and then either invest with the current trend until the trendline is broken, or wait for the trendline to be broken and then invest with the new (opposite) trend.
One of the basic tenets put forth by Charles Dow in the Dow Theory is that security prices do trend. Trends are often measured and identified by “trendlines.” A trendline is a sloping line that is drawn between two or more prominent points on a chart. Rising trends are defined by a trendline that is drawn between two or more troughs (low points) to identify price support. Falling trend-s are defined by trendlines that are drawn between two or more peaks (high points) to identify price resistance.
Investors may be watching other technical indicators such as the Williams Percent Range or Williams %R. The Williams %R is a momentum indicator that helps measure oversold and overbought levels. This indicator compares the closing price of a stock in relation to the highs and lows over a certain time period. A common look back period is 14 days. Barclays Plc (BARC.L)’s Williams %R presently stands at -14.55. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would indicate an overbought situation. A reading from -80 to -100 would indicate an oversold situation.
Barclays Plc (BARC.L)’s Williams Percent Range or 14 day Williams %R presently is at -14.55. In general, if the reading goes above -20, the stock may be considered to be overbought. Alternately, if the indicator goes under -80, this may show the stock as being oversold. The Williams %R indicator helps show the relative situation of the current price close to the period being observed.
We can also take a look at the Average Directional Index or ADX of Barclays Plc (BARC.L). The ADX is used to measure trend strength. ADX calculations are made based on the moving average price range expansion over a specified amount of time. ADX is charted as a line with values ranging from 0 to 100. The indicator is non-directional meaning that it gauges trend strength whether the stock price is trending higher or lower. The 14-day ADX sits at 15.33. In general, and ADX value from 0-25 would represent an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would indicate a very strong trend, and a value of 75-100 would signify an extremely strong trend. At the time of writing, Barclays Plc (BARC.L) has a 14-day Commodity Channel Index (CCI) of 154.61. Developed by Donald Lambert, the CCI is a versatile tool that may be used to help spot an emerging trend or provide warning of extreme conditions. CCI generally measures the current price relative to the average price level over a specific time period. CCI is relatively high when prices are much higher than average, and relatively low when prices are much lower than the average.


A commonly used tool among technical stock analysts is the moving average. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. Moving averages can be very helpful for identifying peaks and troughs. They may also be used to assist the trader figure out proper support and resistance levels for the stock. Currently, the 200-day MA is sitting at 208.83. The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of stock price movements. The RSI was developed by J. Welles Wilder, and it oscillates between 0 and 100. Generally, the RSI is considered to be oversold when it falls below 30 and overbought when it heads above 70. RSI can be used to detect general trends as well as finding divergences and failure swings. The 14-day RSI is presently standing at 60.09, the 7-day is 66.96, and the 3-day is resting at 69.11.

mardi 10 octobre 2017

about Benjamin Graham ... @ MarketWatch by Mark Hulbert

Quote of the day :

"One lucky break, or one supremely shrewd decision — can we tell them apart? — may count for more than a lifetime of journeyman efforts." 

I think Graham was hinting at this when he added: “Behind the luck or the crucial decision, there must usually exist a background of preparation and disciplined capacity. One needs to be sufficiently established and recognized so that these opportunities will knock at his particular door. One must have the means, the judgment and the courage to take advantage of them.”  (By MARK HULBERT @ MarketWatch)

Benjamin Graham

Économiste
Benjamin Graham, économiste, entrepreneur et investisseur américain du XXᵉ siècle, a été reconnu mondialement comme l'investisseur le plus doué de la planète. Wikipédia

jeudi 5 octobre 2017

about ANDAs @ Zacks ...

by Zacks Equity Research
October 04, 2017


Mylan N.V. (MYL) announced that the FDA has approved Abbreviated New Drug Applications (ANDAs) for the generic version of Teva Pharmaceutical Industries Limited’s (TEVA) multiple sclerosis (MS) drug Copaxone (glatiramer acetate) 40 mg/mL (thrice weekly).
Notably, this is the first generic of Copaxone that has been approved.

The FDA also approved a generic for Copaxone 20 mg/mL Once-Daily.

Since Mylan was one of the first applicants to submit a substantially complete ANDA for glatiramer acetate Injection, 40 mg/mL, containing a Paragraph IV certification, the company and other first filers may be eligible for 180 days of generic drug exclusivity.

According to QuintilesIMS, sales of Copaxone 20mg/mL dose was approximately $700 million and $3.64 billion for the 40 mg/mL dose for the 12 months period ending July 31, 2017. Hence, the generic approval is expected to provide a significant boost to Mylan. Moreover, approximately 400,000 or 85% individuals in the United States suffer from MS and relapsing MS.


The news is expected to relieve investors. Mylan’s stock has fallen 16.2% in the last six months compared with the industry’s decline of 16.5%. Mylan continues to face challenges in North America and uncertain regulatory environment in the region which has led the company to defer all major launches in the United States from 2017 to 2018.

Mylan currently has 225 ANDAs pending FDA approval. 44 of these pending ANDAs are potential first-to-file opportunities. However, the company suffered a blow when the FDA issued a complete response letter to its ANDA for generic version of GlaxoSmithKline’s plc (GSK - Free Report) asthma drug Advair Diskus. Advair recorded sales of £1.8 billion in 2016. The company believes approval delays will persist in 2017 thereby impacting business further.  The company believes that increased competition resulting from the FDA's focus on accelerating the approvals of third, fourth, or fifth generics will also impact sales.

Meanwhile, Momenta Pharmaceuticals, Inc. (MNTA - Free Report) along with Sandoz is looking to get approval for their generic version (Glatopa 40 mg) of 40-mg thrice-weekly formulation of Copaxone. Momenta’s sales of Glatopa 20mg continue to do well and have already captured approximately 40% of the market in the United States.